{"entity":{"id":"maximilian-niyazi","kind":"person","name":"Maximilian Niyazi","aka":[],"tldr":"Radiation oncologist who speaks for the Comprehensive Cancer Center Tübingen-Stuttgart and directs radiation oncology at Tübingen University Hospital.","summary":"Prof. Maximilian Niyazi is Speaker of the Comprehensive Cancer Center Tübingen-Stuttgart and Medical Director of the University Clinic for Radiation Oncology in Tübingen. His research focuses on radiotherapy for brain tumours, including target volume delineation guidelines for glioblastoma and combined radio-immunotherapy approaches.","asOf":"2026-09-10","links":[{"label":"Institution profile","url":"https://www.medizin.uni-tuebingen.de/de/das-klinikum/einrichtungen/zentren/tumorzentrum-ccc/vorstand"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Niyazi+M%5BAuthor%5D"}],"tags":["leadership","clinician-scientist","radiotherapy","neuro-oncology"],"related":[],"cancers":["glioblastoma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["ccc-tuebingen"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["radiation-oncology"],"dependsOn":[],"notes":[],"role":"Speaker (Sprecher) of the CCC Tübingen-Stuttgart","institutionId":"ccc-tuebingen","specialisms":["Radiation oncology","Neuro-oncology","Glioblastoma"],"profiles":[{"label":"Institution profile","url":"https://www.medizin.uni-tuebingen.de/de/das-klinikum/einrichtungen/zentren/tumorzentrum-ccc/vorstand"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Niyazi+M%5BAuthor%5D"}],"papers":[{"title":"Counting colonies of clonogenic assays by using densitometric software","journal":"Radiation Oncology","year":2007,"doi":"10.1186/1748-717x-2-4"},{"title":"Fractionated radiotherapy for spinal tumors: A literature review regarding spinal glioma, ependymoma, and meningioma","journal":"Neuro-Oncology Advances","year":2024,"doi":"10.1093/noajnl/vdad158"},{"title":"Dosimetric feasibility analysis and presentation of an isotoxic dose-escalated radiation therapy concept for glioblastoma used in the PRIDE trial (NOA-28; ARO-2022-12)","journal":"Clinical and Translational Radiation Oncology","year":2024,"doi":"10.1016/j.ctro.2023.100706"}],"orcid":"0000-0002-7711-9486"},"route":"/people/maximilian-niyazi/","neighbours":{"cancer":[{"id":"glioblastoma","kind":"cancer","name":"Glioma & glioblastoma","route":"/cancers/glioblastoma/"}],"institution":[{"id":"ccc-tuebingen","kind":"institution","name":"Comprehensive Cancer Center Tübingen-Stuttgart","route":"/institutions/ccc-tuebingen/"}],"journal":[{"id":"radiation-oncology","kind":"journal","name":"Radiation oncology","route":"/journals/radiation-oncology/"}]}}